Abstract:Background Immunotherapy targeting PD-L1 together with platinum-based chemotherapy has demonstrated clinical activity in extensive-stage small cell lung cancer (ES-SCLC). However, brain metastasis seems to be an adverse prognostic factor. Here we report a case of a pretreated ES-SCLC patient with brain metastases who obtained marked clinical benefit from a combination of the anti-PD-1 antibody (toripalimab) together with platinum-based chemotherapy. Methods A 56-year-old male smoker first presented at our hospital on March 17, 2018, with a dull pain in the right chest wall, without obvious cause. The patient underwent a biopsy of the right lung, revealing small cell carcinoma. Between April 20, 2018 and June 27, 2018, the patient received four cycles of platinum-based chemotherapy (irinotecan with carboplatin) and achieved a partial response (PR) (RECIST 1.1). However, at the end of 2019, his condition began to deteriorate. He had left upper abdominal pain without obvious cause, followed by dizziness, headache, unsteady walking, dull pain in the middle and upper abdomen, accompanied by acid regurgitation and belching. CT and MRI showed secondary malignant tumors in the liver, intracranially and in the pancreas with lymph node metastasis. Because the patient refused radiotherapy, from June 2020 he was treated with etoposide (160 mg, every 3 weeks on day 1–3) plus cisplatin (40 mg, every 3 weeks on day 1–3) combined with toripalimab (240 mg, every 3 weeks on day 1). Results Following two cycles of treatment, MRI showed significant shrinkage of the patient's intracranial tumor. After the next sequential 4 cycles of therapy, MRI showed that the intracranial tumor had almost disappeared, CT images showed similar shrinkage of the liver and pancreas tumors. The overall efficacy assessment was PR. The patient tolerated the treatment with no side effects and is experiencing a durable clinical benefit. He now maintains immunotherapy and leads a normal life with no progression at the latest follow up on June 2021. Conclusions Immunotherapy targeting PD-L1 added to platinum-based chemotherapy has been shown to prolong overall survival in ES-SCLC patients. Even in pretreated patients with brain metastases, PD-1 inhibitors plus platinum-based chemotherapy may also play a potential role. This is worthy of further investigation in formal clinical trials.

Chemotherapy combined with bevacizumab for small cell lung cancer with brain metastases: A case report

1439P Brain Radiotherapy Combined with Camrelizumab and Platinum-Based Chemotherapy As First-Line Treatment for Advanced NSCLC with Brain Metastases: A Multicenter, Open-Label, Single-Arm, Phase II Study

Stereotactic Radiosurgery with Whole Brain Radiotherapy Combined with Bevacizumab in the Treatment of Brain Metastases from NSCLC.

Bevacizumab Plus Chemotherapy Versus Chemotherapy Alone for Preventing Brain Metastasis Derived from Advanced Lung Cancer

Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment A cohort study

632 Toripalimab combined with platinum-based chemotherapy as a second-line treatment for small cell lung cancer (SCLC) with brain metastases: a case report

Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report: Nivolumab in SCLC

Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy

Whole Brain Radiotherapy-Based Combined Modality Treatment of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Analysis of Prognostic Factors

Combination Nivolumab with Transcatheter Arterial Chemoembolization for Clinical Remission of Small Cell Lung Cancer: A Case Report

Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer

Brain radiation necrosis treated with bevacizumab in a patient with advanced squamous cell lung carcinoma: A case report

Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

Treatment and survival of patients with small cell lung cancer and brain metastasis

Relationship between the curative effect of chemoradiotherapy and brain metastasis in limited-disease small cell lung cancer

Advances in antiangiogenic treatment of small-cell lung cancer

The Optimal Timing And Courses Of Bevacizumab Added To Chemotherapy For Non-Squamous Non-Small Cell Lung Cancer: Revelations From The Real-World Experience In A Single Chinese Cancer Center

Serplulimab monotherapy in extensive-stage small-cell lung cancer with brain metastasis: a case report

High-Biologically Effective Dose Radiotherapy Improve The Survival Of Small Cell Lung Cancer Patients With Brain Metastases: A Propensity-Matching Analysis

Zimberelimab combined with systemic therapy extended tumor control in post‐radiotherapy cervical cancer with brain metastases: A case report